These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15759039)

  • 1. Animal models of acute myelogenous leukaemia - development, application and future perspectives.
    McCormack E; Bruserud O; Gjertsen BT
    Leukemia; 2005 May; 19(5):687-706. PubMed ID: 15759039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to establish acute myeloid leukemia xenograft models using immunodeficient mice.
    Shan WL; Ma XL
    Asian Pac J Cancer Prev; 2013; 14(12):7057-63. PubMed ID: 24460250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review: genetic models of acute myeloid leukaemia.
    McCormack E; Bruserud O; Gjertsen BT
    Oncogene; 2008 Jun; 27(27):3765-79. PubMed ID: 18264136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BN acute myelocytic leukemia (BNML) (a rat model for studying human acute myelocytic leukemia (AML)).
    Martens AC; Van Bekkum DW; Hagenbeek A
    Leukemia; 1990 Apr; 4(4):241-57. PubMed ID: 2195239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice.
    Zorzoli A; Di Carlo E; Cocco C; Ognio E; Ribatti D; Ferretti E; Dufour C; Locatelli F; Montagna D; Airoldi I
    Clin Cancer Res; 2012 Mar; 18(6):1630-40. PubMed ID: 22383738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Murine models of human acute myeloid leukemia.
    Fortier JM; Graubert TA
    Cancer Treat Res; 2010; 145():183-96. PubMed ID: 20306252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
    Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
    Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons from models of murine erythroleukemia to acute myeloid leukemia (AML): proof-of-principle of co-operativity in AML.
    Moreau-Gachelin F
    Haematologica; 2006 Dec; 91(12):1644-52. PubMed ID: 17145601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal residual disease in leukemia: studies in an animal model for acute myelocytic leukemia (BNML).
    Martens AC; van Bekkum DW; Hagenbeek A
    Int J Cell Cloning; 1990 Jan; 8(1):27-38. PubMed ID: 2403582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human acute myeloid leukemia stem cells.
    Hope KJ; Jin L; Dick JE
    Arch Med Res; 2003; 34(6):507-14. PubMed ID: 14734090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations of the PU.1 Ets domain are specifically associated with murine radiation-induced, but not human therapy-related, acute myeloid leukaemia.
    Suraweera N; Meijne E; Moody J; Carvajal-Carmona LG; Yoshida K; Pollard P; Fitzgibbon J; Riches A; van Laar T; Huiskamp R; Rowan A; Tomlinson IP; Silver A
    Oncogene; 2005 May; 24(22):3678-83. PubMed ID: 15750630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of murine and human acute myeloid leukemia stem cells.
    Deshpande AJ; Ahmed F; Buske C
    Methods Mol Biol; 2009; 568():21-35. PubMed ID: 19582419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of acute myeloid leukemia: towards a patient-oriented, risk-adapted approach.
    Mandelli F; Petti MC; Lo Coco F
    Haematologica; 1998 Nov; 83(11):1015-23. PubMed ID: 9864924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?
    Grove CS; Vassiliou GS
    Dis Model Mech; 2014 Aug; 7(8):941-51. PubMed ID: 25056697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model.
    Uesato N; Fukui K; Maruhashi J; Tojo A; Tajima N
    Exp Hematol; 2006 Oct; 34(10):1385-92. PubMed ID: 16982331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML.
    Romero AI; Thorén FB; Aurelius J; Askarieh G; Brune M; Hellstrand K
    Scand J Immunol; 2009 Sep; 70(3):194-205. PubMed ID: 19703009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
    Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
    Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Xenograft Models of Primary Acute Myeloid Leukemia for the Development of Imaging Strategies and Evaluation of Novel Targeted Therapies.
    Gelebart P; Popa M; McCormack E
    Curr Pharm Biotechnol; 2016; 17(1):42-51. PubMed ID: 26278528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human AML cells in NOD/SCID mice: engraftment potential and gene expression.
    Lumkul R; Gorin NC; Malehorn MT; Hoehn GT; Zheng R; Baldwin B; Small D; Gore S; Smith D; Meltzer PS; Civin CI
    Leukemia; 2002 Sep; 16(9):1818-26. PubMed ID: 12200698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo optical imaging of acute myeloid leukemia by green fluorescent protein: time-domain autofluorescence decoupling, fluorophore quantification, and localization.
    McCormack E; Micklem DR; Pindard LE; Silden E; Gallant P; Belenkov A; Lorens JB; Gjertsen BT
    Mol Imaging; 2007; 6(3):193-204. PubMed ID: 17532885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.